Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis

J O Lindsay, C J Ciesielski, T Scheinin, F M Brennan and H J Hodgson

_Gut_ 2003;52:363-369
doi:10.1136/gut.52.3.363

Updated information and services can be found at:
http://gut.bmj.com/cgi/content/full/52/3/363

References

This article cites 30 articles, 11 of which can be accessed free at:
http://gut.bmj.com/cgi/content/full/52/3/363#BIBL

4 online articles that cite this article can be accessed at:
http://gut.bmj.com/cgi/content/full/52/3/363#BIBL

Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Correction

A correction has been published for this article. The contents of the correction have been appended to the original article in this reprint. The correction is also available online at:
http://gut.bmj.com/cgi/content/full/53/5/774-a

Notes
Inflammatory Bowel Disease

Local delivery of adenoaviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis

J O Lindsay, C J Ciesielski, T Scheinin, F M Brennan, H J Hodgson

Introduction: Interleukin 10 knockout (IL-10−/−) mice spontaneously develop a Th1 cell mediated colitis with many similarities to Crohn’s disease. Daily injections of IL-10 are unable to induce remission in mice with established disease. In contrast, we have shown previously that intravenous administration of adenoaviral vectors encoding IL-10 (AdvmuIL-10) induces hepatic IL-10 release and leads to long term disease suppression with profound systemic immunoregulatory changes.

Aims: To determine whether rectal delivery of AdvmuIL-10 induces localised colonic IL-10 expression without systemic immune suppression, and assess its therapeutic efficacy in IL-10−/− mice with established colitis.

Results: A single rectal infusion of 5×10⁶ PFU AdvmuIL-10 to 10 week IL-10−/− mice resulted in a median level of 27.3 pg/mg IL-10 in colonic homogenates harvested one week later. IL-10−/− mice with established colitis treated with an enema of 5×10⁶ PFU AdvmuIL-10 entered clinical and histological remission whereas empty cassette adenovirus (Adv0) or phosphate buffered saline (PBS) treated mice developed progressive disease. After four weeks, the histological score of AdvmuIL-10 treated mice (4.4 [1.5]) was significantly lower than that of Adv0 (11.1 [1.1]; p<0.001) and PBS (10.9 [1.0]; p<0.001) treated controls. In addition, the stool concentration of IL-1β over the four week experiment was significantly higher in mice treated with saline or Adv0 than in those treated with AdvmuIL-10 (p<0.01).

Conclusion: Local AdvmuIL-10 therapy reverses colitis in IL-10−/− mice without the systemic effects seen after intravenous administration. Gene therapy strategies using adenoaviral vectors encoding immunoregulatory cytokines may prove to be a potent approach to the treatment of chronic inflammatory diseases such as Crohn’s disease.

The chronic gastrointestinal inflammation that characterises Crohn’s disease is associated with loss of tolerance to resident enteric bacteria, activation of immune cells, and leucocytic infiltration. These inflammatory processes are orchestrated by the production of chemokines, proinflammatory monokynes, and Th1 cytokines. Studies of mice in which interleukin (IL)-10 signalling is disrupted provide compelling evidence for the role of this immunoregulatory cytokine in maintaining mucosal homeostasis. Thus both gene targeted IL-10 knockout (IL-10−/−) and IL-10 receptor 2 deficient mice develop a Th1 lymphocyte mediated colitis with many similarities to Crohn’s disease. IL-10 has broad immunoregulatory activity and thus acts to suppress intestinal inflammation on several levels. It diminishes both antigen presentation and IL-12 release, which inhibits differentiation of Th1 lymphocytes. In addition, IL-10 suppresses the release of many other proinflammatory cytokines and chemokines, including tumour necrosis factor α (TNF-α), IL-1, IL-6, and IL-8. Finally, there is strong evidence that IL-10 acts to promote differentiation and augment the activity of regulatory T cells.

Administration of systemic IL-10 injections is sufficient to inhibit proinflammatory Th1 lymphocyte responses and abrogate colitis in both dextran sodium sulphate and CD4+CD45RB+ transfer models of colitis. Furthermore, in vitro studies have shown that exogenous IL-10 downregulates enhanced proinflammatory cytokine release from lamina propria mononuclear cells isolated from patients with Crohn’s disease. Despite this, two recent clinical trials in patients with either steroid naïve or steroid resistant Crohn’s disease have shown that daily systemic IL-10 injections are safe and well tolerated but have minimal therapeutic efficacy compared with placebo. One explanation for these disappointing results is that the pharmacodynamics of daily systemic IL-10 delivery does not allow sufficient mucosal penetration to inhibit the proinflammatory response. Thus strategies that result in a more sustained and focused delivery of IL-10 to the gastrointestinal mucosa may prove effective.

Recently, we have demonstrated that a single systemic injection of an adenoaviral vector encoding murine IL-10 (AdvmuIL-10) targets hepatocytes and results in at least 10 weeks of bioactive IL-10 expression. Unlike daily recombinant IL-10 injections, systemic AdvmuIL-10 therapy induced remission in IL-10−/− mice with established disease, leading to lower clinical and histological scores with reduced faecal proinflammatory cytokine levels. Finally, delivery of IL-10 also appeared to limit the host response to viral vector, as antiderenovirus antibody titres were lower in AdvmuIL-10 treated mice than in littermates treated with control virus. However, in addition to these beneficial effects, systemic AdvmuIL-10 therapy led to generalised immunoregulatory changes in IL-10−/− mice, such as an impaired splenocyte response to lipopolysaccharide (LPS), that may limit its potential in patients with Crohn’s disease. Likewise, clinical

Abbreviations: IL-10, interleukin 10; AdvmuIL-10, adenoaviral vector encoding murine IL-10; Advβgal, adenoaviral vector encoding β-galactosidase; Adv0, empty cassette adenoaviral vector; TNF-α, tumour necrosis factor α; IFN-γ, interferon γ; LPS, lipopolysaccharide; FCS, fetal calf serum; PBS, phosphate buffered saline; DMEM, Dulbecco’s modified Eagle’s medium; CAR, Csfaxxie virus and adenovirus receptor; IPMN, lamina propria mononuclear cell; MOI, multiplicity of infection.
trials of systemic IL-10 have reported a dose dependant but fully reversible anaemia and thrombocytopenia and the long term sequelae of this treatment are not known. It is possible that targeted local IL-10 would be sufficient to treat intestinal inflammation while avoiding the side effects associated with systemic therapy. Thus oral administration of non-pathogenic bacteria (Lactobacillus lactis) that have been genetically modified to secrete murine IL-10 led to histological improvement in dextran sodium sulphate and IL-10−/− models of colitis. Concerns raised by the release of genetically modified organisms into the environment may be avoided by the use of replication deficient adenoviral vectors such as AdvmuIL-10. Adenoviruses have strong tropism for epithelial tissues, and adenoviral vectors delivered per rectum have been shown to induce expression of the delivered transgene within colonocytes. In this paper, we demonstrate the ability of rectal AdvmuIL-10 to induce colonic IL-10 expression and ameliorate established colitis in IL-10−/− mice without the generalised side effects associated with systemic therapy. Furthermore, we show that local AdvmuIL-10 results in a diminished host antipanoviral response compared with control adenoviral vectors.

MATERIALS AND METHODS

General reagents were of research grade and purchased from Sigma (St Louis, Missouri, USA). All reagents used for cell culture were determined to be LPS free using a limulus amebocyte lysate assay (Biowhittaker, Berkshire, UK), as directed by the manufacturer (sensitivity <10 pg/ml).

Adenoviral vectors

The recombinant E1 deleted type 5 adenoviral vectors, encoding murine IL-10 under the transcriptional control of the rous sarcoma virus promoter (AdvmuIL-10), β-galactosidase under the cytomegalovirus promoter (AdvβGal), or having no insert (Adv0), were generously donated by Professor Dallman (Imperial College, London, UK). Viruses were propagated in the 293 human embryonic kidney cell line (Quantum Biotechnology Inc., Canada) and purified by ultracentrifugation through two caesium chloride gradients (Boehringer Mannheim, Lewes, Sussex, UK). The titre of adenoviral vectors was determined by plaque assay on 293 cells. Viral stocks were diluted with 10% glycerol and stored in aliquots at −80°C until use.

In vitro epithelial cell infection

The transformed human colonic epithelial cell lines HT29 and SW620 (ATCC, Maryland, USA) were cultured at a density of 1×10⁵/ml in RPMI 1640 medium (PAA Laboratories Ltd, Yeovil, UK) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, and 100 μg/ml streptomycin (Biowhittaker). Initial experiments demonstrated that at least 95% infection with AdvβGal was obtained with a multiplicity of infection of (MOI) 50:1 and an incubation time of 36 hours; thus these conditions were used in subsequent experiments. Cells were cultured in triplicate, infected with Adv0, AdvmuIL-10, or saline vehicle and cultured for 28 days with weekly passaging. Supernatants were collected after centrifugation and stored at −20°C until assay.

Histological analysis

Samples were routinely processed, embedded in paraffin, sectioned at 5 μm, and stained with haematoxylin and eosin for light microscopic examination. Histological assessment was performed by an investigator (TS) blinded to the treatment group. The terminal ileum and five segments of colon were examined per mouse and each given a histological score from 0 to 4 as described previously; thus a total score for each mouse from 0 (no change in any segment) to 24 (grade 4 changes in all segments) was obtained. Scores of less than 5 were deemed to be within normal limits.

Stool samples

Stool samples were collected weekly from all animals and weighed. Samples were emulsified in 50 μl per 100 μg stool weight of a solution of 1 mg/ml soy trypsin inhibitor and 1 mg/ml phenylmethylsulphonyl fluoride in PBS. Supernatants were collected after centrifugation at 10 000 × g for 15 minutes and stored at −20°C.

Spleen cell cultures

After sacrifice, each spleen was placed in RPMI 1640 supplemented with 10% FCS, 100 U/ml penicillin, and 100 μg/ml streptomycin. Cell suspensions were obtained by passing tissue through a 200 μm nylon mesh. Cell suspensions were washed in Hanks balanced salt solution three times before resuspension in medium. Cells were plated at 2×10⁶/well in 12 well plates (Falcon, Becton Dickinson Labware, USA) in a final volume of 1 ml of medium

Animals

IL-10−/− mice on a C57BL/6 background (purchased from Harlan UK Ltd, Oxon, UK) were backcrossed for one generation onto DBA/1 mice to increase breeding vigour and disease expression. Progeny from the interbreeding of the heterozygous offspring were used in all experiments. Newly bred mice were screened for the homozygote IL-10−/− or wild-type genotype (C57BL/6xDBA1), as described previously. Mice were maintained in specific pathogen free conditions in a laminar flow hood at all times with free access to food and water. All experiments involving animals were approved by the local ethics review process committee and performed under license from the Home Office.

Preliminary experiments demonstrated that under standard laboratory conditions, IL-10−/− animals developed a progressive colitis from four weeks of age. Clinical manifestations of disease included the passage of mucous, diarrhoea, rectal prolapse, and weight loss of greater than 5% of total body weight. Mice were examined weekly, and given a clinical score that consisted of one point for each of the above signs. Previous work has demonstrated a close correlation between the clinical score and histological severity of colitis (correlation coefficient 0.865; Dr T Scheinin, personal communication).

Experimental protocols

Ten week old IL-10−/− mice with established colitis received 5×10⁶ PFU of AdvmuIL-10, Adv0, or phosphate buffered saline (PBS) vehicle as a 100 μl rectal infusion under sedation. Mice were held vertically for one minute and then suspended on tilted racks for a further 10 minutes to prevent seepage. Wild-type C57BL/6xDBA1 mice were used as a negative control. The clinical score of each animal was assessed and stool samples were collected weekly throughout the experiment. Animals were sacrificed by cervical dislocation four weeks after adenoviral therapy. Serum was collected via cardiac puncture, spleens were harvested, stool samples collected, and serial segments of colon, caecum, and ileum were fixed in 10% neutral buffered formalin for histological analysis. In a separate experiment, IL-10−/− mice that had received saline or AdvmuIL-10 by rectal instillation were sacrificed after seven days. The liver, spleen, and colon of these animals were weighed and homogenised in 5 μl PBS per mg tissue. Supernatants were harvested after centrifugation and stored at −20°C until assay.
Local delivery of adenoviral vectors

with or without LPS 10 µg/ml recombinant mull-10 10 ng/ml (Schering Plough, New Jersey, USA), 10 µg/ml neutralising rat antimurine IL-10 antibody (JES52A5; donated by DNAX Research Institute), or a rat IgG1 isotype control (OX20; ATCC). Cultures were maintained for 24 hours before supernatants were harvested and stored at −20°C.

Measurement of serum antiadenoviral antibody response

The neutralising adenovirus antibody response was analysed in serum from untreated or treated IL-10−/− mice four weeks after gene transfer with 5×10⁹ PFU of AdvmuIL-10, Adv0, or PBS vehicle. Serum samples (100 µl) were heat inactivated at 56°C for 30 minutes and diluted twofold in serum free Dulbecco’s modified Eagle’s medium (DMEM). Each dilution was incubated for 90 minutes at 37°C with 2×10⁶ PFU of Advβgal, and applied in duplicate to 80% confluent 293 cells on a 96 well plate. After one hour at 37°C, 50 µl of DMEM containing 10% FCS was added to each well, and cells were cultured for a further 36 hours. Cell supernatants were then removed and replaced with 30 µl of 0.25 mM Tris HCl, pH 7.8.

Cytokine analysis

Cytokine concentrations were measured by sandwich ELISA using paired antibodies according to the manufacturer’s recommendations (IL-10 and TNF-α were purchased from Pharmingen, Sorentino, California, USA; interferon γ (IFN-γ) was purchased from Genzyme diagnostics, USA; IL-1β was purchased from R&D Systems (Abingdon, Oxon, UK)).

Statistical analysis

Data that exhibited a normal distribution were analysed using a two tailed t test; for comparison of more than two means a two way analysis of variance (ANOVA) was performed.

RESULTS

In vitro infection of epithelial cell lines with AdvmuIL-10 induces bioactive murine IL-10 release

In order to ascertain whether AdvmuIL-10 induces IL-10 secretion from epithelial cells, cultures of the human colon epithelial cell lines HT29 and SW620 were infected with AdvmuIL-10 at an MOI of 50:1 for 36 hours; separate wells were infected with Adv0 or saline vehicle as controls. Supernatants were sampled daily, and cultures were passaged weekly. No IL-10 was detected in the supernatants of Adv0 or vehicle treated cells. In contrast, 36 hours after AdvmuIL-10 infection, the supernatants of HT29 and SW620 cells contained 297 (44) ng/ml and 790 (43)
ng/ml mullIL-10, respectively (mean (SEM)). IL-10 release continued for the 28 days of the experiment, as shown in fig 1. In order to confirm that this IL-10 was bioactive, the ability of the supernatants from AdvmuIL-10 infected HT29 cells to inhibit LPS induced TNF-α release from cultures of RAW cells was compared with recombinant murine IL-10. mullIL-10 10 ng/ml reduced TNF-α release to 17.5 (0.7)% of LPS stimulated levels whereas a 1/10 dilution of the supernatant of AdvmuIL-10 infected HT29 cells reduced TNF-α release to 15.8 (0.29)%. Addition of a monoclonal antimurine IL-10 antibody (but not isotype control antibody) abrogated this inhibitory effect completely (fig 1).

Rectal instillation of AdvmuIL-10 results in localised colonic IL-10 expression

Systemic delivery of adenoviral vectors predominantly targets hepatocytes although some splenic and colonic expression of the delivered transgene has been reported. In order to assess whether rectal AdvmuIL-10 delivery results in localised colonic IL-10 release, 5x10⁸ PFU of AdvmuIL-10 or PBS vehicle were delivered to 10 week old IL-10−/− mice either by tail vein injection or by rectal instillation (n=3/group). Mice were sacrificed one week after adenoviral administration. IL-10 concentration in colonic homogenates from mice that had received rectal AdvmuIL-10 was mean 26.5 (SEM 8.7) pg/mg.

Figure 3  Local adenoviral vector encoding murine interleukin 10 (AdvmuIL-10) was therapeutic for established murine colitis. IL-10−/− mice (n=10/group) with clinical evidence of colitis and C57BL/6xDBA1 wild-type controls (n=5/group) received 5x10⁸ PFU of AdvmuIL-10, empty cassette adenoviral vector (Adv0), or vehicle by rectal instillation under light sedation. (A) Clinical score (one point each for rectal mucous, rectal prolapse, diarrhoea, and weight loss >5% body weight) and (B) stool IL-1β levels were measured weekly, and are expressed as mean (SEM) for each group. **p<0.01, ***p<0.001, two way ANOVA.

Figure 4  Local adenoviral vector encoding murine interleukin 10 (AdvmuIL-10) therapy reduced histological colitis scores in IL-10−/− mice with established disease. Four weeks after therapy, mice were sacrificed by cervical dislocation and sections of five regions of the colon were processed for histology. Representative samples from an IL-10−/− mouse treated with empty cassette adenoviral vector (Adv0) (A) and AdvmuIL-10 (B) are shown. An investigator, blinded to treatment group, gave each section an inflammatory score from 0 to 4. The sum of these scores is shown for each mouse (C), with the bar representing the mean for the group (**p<0.01 versus IL-10−/− saline group; ***p<0.001 versus IL-10−/− Adv0 group; one way ANOVA with Bonferroni correction).
compared with 13 (6.5) pg/mg in mice that had received an intravenous injection. In contrast, while liver and spleen IL-10 concentrations after rectal AdvmuIL-10 administration did not differ significantly from the background seen in PBS treated controls (the sensitivity of the ELISA was approximately 8 pg/mg), IL-10 concentrations in the liver and spleen of mice given an intravenous injection were significantly elevated (52.5 (22.5) pg/ml and 5.7 (4.3) pg/ml, respectively) (fig 2).

Local AdvmuIL-10 treatment is therapeutic for established colitis in IL-10−−/− mice

IL-10−−/− mice develop a spontaneous enterocolitis associated with weight loss, passage of mucous, rectal prolapse, and diarrhoea. It has been reported that daily injections of recombinant murine IL-10 prevent disease but are not sufficient to reverse established colitis.14 In order to determine the therapeutic efficacy of local AdvmuIL-10 delivery, 10 week old IL-10−−/− mice with established colitis received a single rectal instillation of 5×10⁷ PFU of AdvmuIL-10, Adv0, or PBS vehicle. Wild-type mice received the same treatment to act as a negative control. IL-10−−/− mice that received AdvmuIL-10 demonstrated a significant improvement in their colitis scores over the four week experiment whereas those that had received Adv0 or vehicle continued to develop progressive disease (fig 3). Thus the mean (SEM) clinical score in the AdvmuIL-10 group fell from 1.8 (0.13) to 0.4 (0.16) whereas clinical scores increased from 1.4 (0.27) to 2.5 (0.27) and from 1.8 (0.22) to 2.6 (0.13) in the PBS and Adv0 treated groups, respectively (p<0.001 for both Adv0 and PBS compared with AdvmuIL-10; two way ANOVA). No clinical evidence of colitis was detected in any both Adv0 and PBS compared with AdvmuIL-10; two way ANOVA). No clinical evidence of colitis was detected in any

IL-10−−/− mice that had received rectal Adv0, AdvmuIL-10, or PBS vehicle (data not shown). Analysis of weekly stool samples demonstrated that the progressive colitis observed in the Adv0 and PBS treated IL-10−−/− mice was associated with release of significantly higher levels of the proinflammatory cytokine IL-1β than AdvmuIL-10 treated IL-10−−/− mice (p<0.01; fig 3). IL-1β was not detected in stools collected from wild-type mice treated with Adv0, AdvmuIL-10, or PBS vehicle (data not shown).

Histological analysis of colonic tissue from 10 week old IL-10−−/− mice demonstrated a marked colitis with a histological score of 9.4 (1.3) (n=5). The histological score of colitic IL-10−−/− mice four weeks after local instillation of 5×10⁷ PFU of Adv0 or saline vehicle increased to 11.1 (1.1) and 10.9 (1.0), respectively. The histological severity of colitis was consistent throughout the colon (data not shown). In contrast, a single dose of rectal AdvmuIL-10 induced histological remission in IL-10−−/− mice with established disease (fig 4). Thus four weeks after AdvmuIL-10 therapy the mean histological score had fallen to 4.4 (1.5) (p<0.01 compared with saline; p<0.001 compared with Adv0 therapy); this was not significantly different from the scores of age matched wild-type mice that had received a rectal enema of saline, Adv0, or AdvmuIL-10 four weeks previously (1.2 (0.5), 3.2 (0.8), and 1.4 (0.6), respectively). Interestingly, local AdvmuIL-10 therapy ameliorated histological colitis throughout the colon as there were no significant differences between the histological scores of the proximal and distal sections of the colon in AdvmuIL-10 treated mice (data not shown).

Local AdvmuIL-10 treatment has no effect on TNF-α release from LPS stimulated splenocytes.

IL-10−−/− mice challenged with LPS released elevated levels of proinflammatory cytokines and suffered higher mortality than wild-type controls.16 We have reported that a single systemic injection of AdvmuIL-10 is sufficient to inhibit the elevated TNF-α and IFN-γ release from LPS stimulated splenocytes harvested 10 weeks after therapy.17 In order to determine the systemic effects of local AdvmuIL-10 therapy, we compared TNF-α release from LPS stimulated spleen cells harvested from mice used in the above experiments. TNF-α release from unstimulated splenocytes was below the sensitivity of the ELISA for all animals (<40 pg/ml). As expected, LPS (10 µg/ml) induced significantly higher levels of TNF-α from splenocytes harvested from IL-10−−/− mice than wild-type controls (964 (266) pg/ml and 98 (21) pg/ml, respectively; p<0.02, two tailed t test). However, in contrast with systemic delivery, prior treatment of IL-10−−/− mice with rectal AdvmuIL-10 had no effect on TNF-α release (fig 5). Thus TNF-α release from LPS stimulated splenocytes harvested from IL-10−−/− mice that had received rectal Adv0, AdvmuIL-10, or saline four weeks previously was 1414 (530) pg/ml, 845 (399) pg/ml, and 964 (266) pg/ml, respectively. Furthermore, local AdvmuIL-10 therapy ameliorated TNF-α release in LPS stimulated splenocytes of IL-10−−/− mice that had been treated with rectal AdvmuIL-10 to the same extent (1386 (792) pg/ml with OX20 isotype control compared with 1406 (676) pg/ml when cultured with JES52A5 anti-IL-10 antibodies). As a positive control for this experiment, TNF-α release from LPS stimulated splenocytes harvested from saline treated wild-type mice cultured with either JES52A5 or the OX20 was examined. As predicted, neutralising endogenous IL-10 significantly increased TNF-α release (533 (60) pg/ml with JES52A5 compared with 138 (26) pg/ml with OX20; p<0.02 by two tailed t test).

Neutralising antiadenovirus antibody response is diminished in AdvmuIL-10 treated IL-10−−/− mice

Previous studies have shown elevated titres of antiadenovirus antibodies in mice treated with adenoviral vectors.18 We hypothesised that the neutralising antibody response to AdvmuIL-10 vectors would be diminished, as the protein encoded for by this virus will act to suppress both T cell activation and antigen presentation. A bioassay was used to detect the presence of antibodies directed to adenoviral proteins in the serum of mice that had received a rectal infusion of Adv0, AdvmuIL-10, or saline vehicle four weeks previously. Serum from both IL-10−−/− and wild-type mice that had received rectal Adv0 contained neutralising antiadenovirus antibodies were compared with serum from mice that had received saline (p<0.001 two way ANOVA; fig 6). However, there was no difference in the antiadenovirus antibody titre in serum from IL-10−−/− mice that had received rectal AdvmuIL-10 compared with those that had received saline. Interestingly, the diminished antiadenoviral response to AdvmuIL-10 was less pronounced in wild-type mice than in IL-10−−/− mice.
ver occurs every 2–3 days. This observation is surprising considering that colonic epithelial cell turnover is rapid and may represent LPMN cell infection. Furthermore, Wirtz et al have reported that the ratio of LPMN cells to epithelial cells

Figure 6 Rectal adenoviral vector encoding murine interleukin 10 (AdvmuIL-10) induced a diminished antiadenoviral response in IL-10−/− mice. The neutralising antiadenovirus antibody titre was analysed in serum from (A) IL-10−/− and (B) wild-type mice four weeks after rectal instillation of 5×10^7 PFU of AdvmuIL-10, empty cassette adenoviral vector (Adv0), or saline vehicle. Serial serum dilutions were incubated for 90 minutes at 37°C with 2×10^6 PFU of adenoviral vector encoding β-galactosidase (Advβgal) and applied in duplicate to 80% confluent 293 cells on a 96 well plate. After one hour at 37°C, 50 µl of Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum was added to each well, and cells were cultured for a further 36 hours. Cell supernatants were then removed and assayed using a β-galactosidase substrate solution. In this assay, a low optical density reflects a high titre of serum antiadenoviral antibodies. Results are expressed as mean (SEM) optical density for each group. ** p<0.001 compared with saline treated mice, two way ANOVA).

DISCUSSION

We have explored the potential of local AdvmuIL-10 administration as a therapy for intestinal inflammation. This strategy has the advantage that IL-10 delivery is targeted to the sites of inflammation which may prevent the side effects associated with high dose systemic IL-10 administration. The use of the IL-10−/− model of colitis allows accurate determination of the site of IL-10 expression after local AdvmuIL-10 delivery. In addition, as daily systemic injections of murine IL-10 are unable to reverse established colitis in this model, it allows a comparison of the therapeutic efficacy of local AdvmuIL-10 and recombinant IL-10 injections.

Adenoviral vectors bind to cell surface integrins (αvβ3 and αvβ5) and gain entry by receptor mediated endocytosis using a receptor such as the Coxsackie virus and adenovirus receptor (CAR). CAR mRNA can be detected in human intestinal tissue by northern blotting. Thus infection of human colonic epithelial cells with AdvmuIL-10 in vitro resulted in the release of high levels of functional IL-10 as determined by a specific bioassay. The effect of the secreted murine IL-10 on epithelial cell function was not assessed, as despite 73% amino acid homology between murine and human IL-10 proteins, murine IL-10 has no activity on human cells.

The presence of CAR on murine colonic epithelial cells has not been determined. However, recent reports have suggested that the MHC class I receptor may also function as a high affinity receptor for adenoviral vectors. Irrespective of this, previous studies in mice have demonstrated that colonic administration of adenoviral vectors leads to colonic reporter gene expression, which peaks at 48–72 hours. These findings were confirmed by the significant levels of IL-10 that were detected in colonic homogenates of IL-10−/− mice one week after local AdvmuIL-10 administration. The duration of IL-10 expression in this experiment is surprising considering that colonic epithelial cell turnover occurs every 2–3 days. However, Foreman et al also reported low level β-galactosidase expression for up to 180 hours after colonic Advβgal administration. Although rectal administration of adenoviral vectors predominantly targets the colonic epithelial cell, some expression has been reported in lamina propria mononuclear (LPMN) cells. Thus the late phase of gene expression after local adenoviral vector administration may represent LPMN cell infection. Furthermore, Wirtz et al have reported that the ratio of LPMN cells to epithelial cells infected by rectal adenoviral administration is increased in mice that have colitis. This may explain the prolonged duration of IL-10 expression that we report after AdvmuIL-10 delivery to IL-10−/− mice with established colitis. In addition, AdvmuIL-10 induces a diminished host antiadenovirus response in IL-10−/− mice compared with control vectors that may also permit prolonged IL-10 expression.

Whereas systemic AdvmuIL-10 administration leads to IL-10 expression in the liver, spleen, and colon, IL-10 protein was not detected in the liver and spleen of IL-10−/− mice that received AdvmuIL-10 as an enema. The absence of systemic IL-10 activity after local AdvmuIL-10 therapy was confirmed by experiments examining the response of harvested splenocytes to stimulation with LPS. Local delivery of replication deficient adenoviral vectors was well tolerated and did not exacerbate intestinal inflammation. Studies of adenoviral vectors encoding non-immunoregulatory proteins have demonstrated host antivirus immune responses that limit the duration of gene expression and prevent retreatment. However, in contrast with the marked antibody response to control vectors, local AdvmuIL-10 delivery significantly diminished the host antiadenoviral response in IL-10−/− mice. It is interesting that the reduction in antiadenoviral response seen with AdvmuIL-10 administration is not as marked in wild-type mice in IL-10−/− mice. The explanation for this dichotomy is not clear but is likely to represent alterations in B cell maturation in IL-10−/− mice.

IL-10−/− mice develop a spontaneous Th-1 cell mediated enterocolitis with many similarities to Crohn’s disease. Steidl et al investigated the therapeutic efficacy of local IL-10 delivery using bacteria that had been genetically modified to secrete high levels of IL-10. A four week oral course of these bacteria led to a 75% reduction in the histological severity of colitis in IL-10−/− mice. However, this therapy was administered to three week old mice prior to the onset of their disease. In contrast, we demonstrated that, unlike daily IL-10 injections, a single AdvmuIL-10 enema was capable of reversing established disease in IL-10−/− mice. Furthermore, clinical remission was maintained for at least four weeks after therapy. The dramatic improvement in clinical score was associated with a fall in the levels of the proinflammatory cytokine IL-1ß that was detected in high concentrations in the stool of IL-10−/− mice with colitis. Most strikingly, rectal AdvmuIL-10 therapy led to a 60% reduction in the histological severity of
colitis compared with control treated mice. Thus a single dose of IL-10 gene therapy delivered directly to the colon was sufficient to suppress established disease in IL-10−/− mice for at least four weeks.

The mechanisms by which IL-10 induced by AdvmuIL-10 therapy could have diminished disease severity in the intestine were not addressed directly in our experiments. However, they include downregulation of antigen presenting cell activity and inhibition of proinflammatory cytokine production. The fact that the therapeutic effects of AdvmuIL-10 therapy persisted for at least four weeks and extended throughout the colon suggest that its mechanism of action may extend beyond the local suppression of proinflammatory cytokine release. An analogous situation occurs in mice with collagen induced arthritis in which an intraperitoneal injection of AdvmuIL-10 is therapeutic for both the treated and contralateral paw.75 As in our experiments, the duration of this therapeutic effect persisted far longer than the period in which local IL-10 can be detected. Thus it is possible that local IL-10 release induces differentiation or activation of regulatory T cell clones. This hypothesis is supported by studies of transgenic mice transgenic mice secrect lower levels of Th1 cytokines and higher levels of transforming growth factor β than controls.69

Thus delivery of AdvmuIL-10 directly to the intestinal lumen provides local IL-10 production minimising the side effects associated with systemic therapy. Most strikingly, local AdvmuIL-10 therapy induces clinical and histological remission in IL-10−/− mice with established colitis. The concept of local gene delivery as a therapy for intestinal inflammation is supported by the demonstration that intracellular administration of an E1 deleted adenoviral vector expressing IL-18 antisense miRNA inhibits mucosal IFN-γ release and suppresses inflammation in the transfer model of colitis.76 However, patients with Crohn’s disease are not IL-10 deficient and may mount an immune response to AdvmuIL-10, as seen in wild-type mice. This would limit the duration of a therapeutic response and prevent retreatment. Alternative viral vectors may be more appropriate for clinical trials of IL-10 gene therapy than the replication deficient adenoviral vectors used in the current study. Adeno-associated viruses are less immunogenic, and by integrating into the host genome have been shown to provide long term gene expression in the intestinal tract.77 Furthermore, therapy could be targeted to sites of active disease using an inflammation inducible C3-tat/HIV promoter that induces IL-10 release in response to inflammatory stimuli such as TNF-α.78

In conclusion, local gene therapy strategies using viral vectors encoding immunoregulatory cytokines may prove to be a potent approach to the treatment of chronic inflammatory diseases such as Crohn’s disease.

ACKNOWLEDGEMENTS

We gratefully acknowledge Patricia Green for her technical assistance, and Philip Connolly who kindly performed the histological processing. This work was supported by the Digestive Diseases Foundation and a Clinical Training Fellowship from the Medical Research Council of the UK.

REFERENCES


PostScript

LETTERS

If you have a burning desire to respond to a paper published in the Gut, why not make use of our “rapid response” option? Log on to our website (www.gut.nlin.com), find the paper that interests you, and send your response via email by clicking on the “letters” option in the box at the top right-hand corner. Providing it isn’t libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read letters” on our homepage.

The editors will decide as before whether to publish it in a future paper issue.

Investigation of chronic diarrhoea

I congratulate the authors of the recently revised “BSG guidelines for the investigation of diarrhoea” for their excellent overview of this important clinical problem (Gut 2001; 52(suppl V):v1–15). I would however take issue with the suggestion that measurement of stool volumes in outpatients is impractical. In my experience such measurement is readily achievable and cheap, merely requiring a suitable container and some weighing scales. A three day stool collection should be considered early in the investigation of chronic diarrhoea, particularly if a factitious aetiology is suspected which is unfortunately often undiagnosed and over investigated.

R C G Pollok
Department of Gastroenterology, St George’s Hospital, London, SW17 0QT, UK
rpollok@sghmsi.ac.uk

Reference

Authors’ reply

We welcome Dr Pollok’s comments on the use of a three day stool collection in the investigation of chronic diarrhoea. Our concern about its use in the outpatient setting, and particularly when factitious diarrhoea is suspected, is that collection is unsupervised and potentially susceptible to interference. It was for this reason that inpatient collection was suggested. Furthermore, we think there will be widespread doubt by clinicians about the acceptability of this approach. Excepting these caveats, we agree that it is a relatively simple and effective way to assess stool volume which may limit the need for other investigations in these patients.

P Thomas, A Forbes
St Mark’s Hospital, Watford Road, Harrow HA1 3UJ, UK
Correspondence to: Dr A Forbes; aalastair.forbes@slht.nhs.uk

Interstitial pneumonia associated with autoimmune pancreatitis

We read with interest the article by Kamisawa et al reporting IgG4 positive plasma cells in peripancreatic tissue, extrahepatic bile duct, gall bladder, and salivary gland (Gut 2003;52:683–7). The association of retroperitoneal fibrosis and sclerosing pancreatitis with IgG4 bearing plasma cells in the tissues of both lesions has been also reported.

We would like to report the first case of interstitial pneumonia associated with autoimmune pancreatitis and IgG4 positive plasma cells in the interstitium.

Hyperplasyma was detected in a routine blood examination in a 63 year old man who had been treated for duodenal ulcer at a clinic. He was admitted to our hospital for further examination. He did not complain of epigastralgia or back pain. Serum amylase was 323 (39–130 IU/L), IgG was elevated to 2350 (800–1600 mg/dl), and IgG4 was 1690 (<80 mg/dl). Antiinflammatory antibody, anti-SS-A antibody, anti-SS-B antibody, rheumatoid factor, and antinuclear muscle antibody were all negative. Abdominal ultrasonography and computed tomography (CT) showed swelling of the head and tail of the pancreas. Endoscopic retrograde pancreatography showed irregular narrowing of the main pancreatic duct in the head and tail. Magnetic resonance cholangiography showed stricture stenosis of the lower common bile duct. The patient was diagnosed with autoimmune pancreatitis but he refused steroid therapy and was followed as an outpatient.

Three months later, henemysoning of the bilateral lower lung field was detected in a follow up abdominal CT. Chest CT revealed ground glass attenuation in the middle and lower lobe, and henemysoning predominantly at the back of the lower lobe, bilaterally (fig 1A). (Figure 1 (A–D) is available for viewing online at http://gut.bmjournals.com/cgi/eletters/52/5/683 #127.) Retrospectively, a slight reticular shadow in the lower lung field was detected in the chest roentgenogram taken at the first admission but the lesion had progressed over three months. He was readmitted for further examination. He had a history of smoking 30–40 cigarettes a day for approximately 40 years. IgG was 3934 mg/dl, IgG4 was 2690 mg/dl, KL-6 was 1440 (<500 u/ml), serum amylase was 142, and lipase was 121 (0–190 U/L). Schirmer’s test indicated a decrease in lacrimal secretion. Swelling of the head and tail of the pancreas were not changed on abdominal ultrasonography and CT.

With gallium scintigraphy, uptake was observed bilaterally at the back of the lower lobe, suggesting active pneumonia. Histology obtained by transbronchial lung biopsy from segment 8a of the right lobe showed marked thickening of the alveolar septum with marked infiltration of plasma cells and lymphocytes (fig 1B). Immunostaining with IgG4 was performed with the immunoperoxidase method (mouse antihuman IgG4; ICN Biomedicals, Inc, Ohio, USA). Immunostaining of IgG4 positive plasma cells was detected in the alveolar septum (fig 1C).

Macrophages in the alveoli are considered to be due to smoking which often coexists with interstitial pneumonia in smokers. Because interstitial pneumonia associated with autoimmune pancreatitis was strongly suggested, prednisolone (40 mg/day) was administered for two weeks and then the dose was tapered. Chest CT taken two weeks after treatment showed that the ground glass attenuation in the middle and lower lobe had disappeared whereas the henemysoning remained (fig 1D).

Abdominal ultrasonography performed two weeks after treatment showed a marked decrease in the swelling the pancreas.

In the present case, infiltration of IgG4 positive plasma cells in the interstitium strongly suggests that the intestinal lung disease was associated with autoimmune pancreatitis. Interstitial pneumonia associated with Sjogren’s syndrome is unlikely in this case although there was decreased lacrimal secretion. Sicca syndrome observed in autoimmune pancreatitis is distinguishable from classical Sjogren’s syndrome in that it is negative for anti-SS-A or anti-SS-B antibodies, serum IgG4 is elevated, and infiltration of IgG4 positive plasma cells in the salivary glands is observed.

Autoimmune pancreatitis, in some cases, may be part of a systemic disease associated with IgG4.

T Taniguchi, M Ko, S Seko, O Nishida, F Inoue, H Kobayashi, T Saijo, M Okamoto
Department of Internal Medicine, Radiology, and Pathology, Ohtsu Red Cross Hospital, Ohtsu, Japan

T Fukuse
Department of Thoracic Surgery, Kyoto University Faculty of Medicine, Kyoto, Japan

Correspondence to: Dr T Taniguchi, Department of Internal Medicine, Ohtsu Red Cross Hospital, 1-1-25 Nagara, Ohtsu, Shiga Ohtsu, Japan

References

Author’s reply

We thank Dr Taniguchi et al for the interesting presentation of interstitial pneumonia associated with autoimmune pancreatitis (AIP). We have experienced 24 cases of AIP but no cases showed interstitial pneumonia clinically. Recently, we histologically examined the organs of eight patients with AIP using anti-IgG4 antibody. IgG4 positive plasmacytic infiltration was detected in the portal area of the liver, gastric mucosa, colonic mucosa, and bone marrow as well as in the pancreas, peripancreatic tissue, extrahepatic bile duct, gall bladder, salivary gland,

www.gut.nlin.com

Gut 2004;53:770–774
and lymph nodes of patients with AIP. However, few IgG4 positive plasma cells were observed in identical control specimens. From these findings, we proposed a new clinicopathological entity of IgG4 related autoimmune disease, and stressed that AIP is not simply pancreatitis but a pancreatic lesion involved in this systemic autoimmune disease. As IgG4 positive plasmacytic infiltr- 

The diagnostic dilemmas in discrimination between pancreatic carcinoma and chronic pancreatitis

In response to the letter of Harlozinska-Szymyrka and Strutyńska-Karpinska (Gut 2003;52:879–81), we agree with the remarks made in relation to the difficulties in discriminating between chronic pancreatitis and adenocarcinoma using currently employed diagnostic imaging and tumour marker analysis. Our study was aimed at determining the risk of cancer development in patients with proven chronic pancreatitis, examining age and sex standardised incidence ratios calculated from the number of observed cases of pancreatic cancer in our cohort of 373 patients with predominantly alcohol related chronic pancreatitis to the number of cases expected in the National Cancer Registry. Our study design did not take into consideration diagnostic dilemmas and focused purely on cancer risk in our cohort of patients using defined stringent criteria. Indeed, we previously underlined the interest of biological markers to this discrimination (for example, CA19-9 and circulating K-ras)17; however these markers have problems with both sensitivity and specificity.

We acknowledge that given the difficulties in diagnosing cancer in this situation, the establishment of new tumour markers such as tissue polypeptide specific antigen (TPS)15 with proven good sensitivity and specificity should provide for progress in the future. Is has to be stressed however that TPS, a marker of proliferation activity, is not specific to pancreatic cancer, and other digestive and non-digestive cancers as well as benign chronic disorders may have high levels of this antigen. In this setting validated data concerning tumour markers, either alone or in combination, in distinguishing pancreatic cancer from chronic pancreatitis should prove important in diagnostic situations.

References


In search of the correct strategy for preventing the spread of HCV infection

Hepatitis C virus (HCV) infection is an emerging global healthcare issue. Apart from affecting approximately 3% of the world population, HCV is also a silent disease—the majority of incidences go unrecognised and serve unknowingly as sources of infection to others.18 Add to that the scant information defining the transmission routes and rates of HCV, the programme presented by Skipper et al in their paper evaluating the diagnosis and prevention of HCV in a prison outreach clinic (Gut 2003;52:1500–4) seems a model that could significantly constrain a situation that appears to be reaching epidemic proportions, especially here in Southern Italy. Studies on the epidemiology of HCV infection in Italy have shown that this infection represents a major health problem throughout Southern Italy, with a prevalence of up to 12.6% in the general population.19,20 Also, HCV has been linked to the high incidence and mortality rates for liver cancer found in our region (standardised incidence rates per 100 000 inhabitants: 18.9 male, 13.2 female; mortality rates 15.2 male, 9.0 female).21 Between January 2000 and December 2001, we performed a cross sectional study of 5844 individuals (4260 men; 1584 women) from the general population and from five select groups in the city of Naples, with the purpose of assessing the prevalence of HCV infection in select groups with different exposure patterns in Southern Italy. Below are the preliminary data from this study:

- general population (n = 1972; prevalence 8.5%).
- imprisonment (n = 524; prevalence 37.4%).
- intravenous drug use (n = 1436; prevalence 31.8%).
- haemodialysis (n = 678; prevalence 2.9%).
- routine medical examination of patients (n = 453; prevalence 12.6%); and
- health care workers at the National Cancer Institute of Naples (n = 781; prevalence 6.4%).

Our findings confirm the high prevalence among drug users (31.8%) but the highest prevalence was found among male prisoners (37.4%), particularly those in the 30–49 year age range (47.3%). In fact, we concur with Skipper et al that “those involved with IDU frequently pass through the penal system and spend time in prisons” thus indicating a probable interrelationship between these two groups.

Our other findings from this study shed light on the unusually high prevalence of this disease in the general population of Southern Italy. Previous reports have shown that the prevalence of HCV infection is generally low in the general population of most industrialised countries (<3%). In Southern Italy, the high prevalence of HCV infection may be the result of past iatrogenic transmission, aggra- 
vated by:

- (1) extensive use of glass syringes or non-
sterile syringes; and
- (2) social conditions which may indirectly favour the spread of infection:

- general poverty,
- poor education etc.”10, and
- especially among females, haemodialysis procedures.

Prisons do play a significant role in the hepatitis C epidemic, especially as the same social conditions mentioned above which may facilitate spread of infection also predict imprisonment.11 In fact, a disproportionate share of the burden of HCV infection is found among those who pass through correctional facilities.12 As stated previously, HCV seroprevalence is high among this group. A history of incarceration is one of the strongest associations with HCV seropositivity.13 Yet despite these high levels, reports of HCV transmission in the prison setting are uncommon.14 In fact, studies have revealed that an overwhelming number of these infections are being brought into prisons via inmates who are already previously infected; drug users are most likely to become infected with HCV at the beginning of their addiction—long before being imprisoned for the first time.15 Yet it must be taken into account the fact that the dynamic movement of people in and out of prisons makes it very difficult to detect transmission. While the available data do not prove that infections are acquired in prison, they do indicate prisons as high risk settings for the spread of HCV.16

What is of great concern to us are the implications of the previous and following data:

- HCV is easily transmitted parenterally.
Our prisons are overcrowded (the Secondigliano prison located in Naples, for example, has 1350 prisoners and only 760 beds).

In Southern Italy, the health system in general is less efficient and less meticulous than that in the north of Italy (and in the rest of the EU and in the USA).

We have no harm reduction programmes in place.

The limited availability of prevention methods has been linked to the transmission of HCV infection. This association, and its relation to inadequate management of a medical problem, surely opens up our National Health System to costly retaliations. If it can be proven that an inmate contracted HCV while incarcerated, due to a lack of sufficient care and prevention on the part of the system, he then has the right to seek judicial indemnification—a costly process for all concerned.

How much more economical to initiate admission screening programmes in our overcrowded prisons where, as detailed above, there is an identifiable elevated risk. By so doing, we move one step closer to correcting a problem that is grossly out of control. As HCV is associated with different kinds of diseases (liver, possibly non-Hodgkins lymphoma) and with autoimmune diseases (cerebrolinacenia, thyroiditis, Hashimoto thyroiditis), which develop after the virus has caused immune system alterations,10 improving health screening on admission to prison presents a unique opportunity to identify health needs and plan health services at an early stage.11

In fact, studies have found that screening provides a preventive function for those who had previously presented for a hepatitis C test, regardless of the result, were less likely to have recently engaged in high risk behaviour (that is, sharing injecting equipment).12

How much more economical to initiate a good educational harm reduction programme such as that implemented by Skipper et al.13 Correctional interventions of this kind stand to benefit not only the inmates themselves and their families and partners, but also the public health of the communities to which the vast majority of inmates return.14 By implementing such a programme, the healthcare system would be doing its job, demonstrating efficient management of a crucial problem and sustaining the welfare of its people.

M Montella, A Crispo, J Jynn-Bellezza National Cancer Institute, Naples, Italy

Correspondence to: Dr M Montella, epidemiologia.intf@tin.it

References


Cross reactivity due to positive canrenone interference

Canrenone is a selective competitive inhibitor of the aldosterone receptor and a diuretic drug commonly used in the treatment of cirrhotic patients both with and without ascites.1 The aim of our observation was to determine if canrenone cross reacts with aldosterone in an immunoradiosorbent assay kit used for quantitative evaluation of the aldosterone system, according to the Child–Pugh classification for liver cirrhosis.2 Canrenone, for in vitro experiments, was a gift from GElne Pharma (Group Therabel) Diagnostics. Canrenone, potassium canrenonate, and spironolactone are often used with digoxin in clinical practice and can cause false elevations in common assays for digoxin (that is, AxSym MEIA-Abbott) due to negative cross reactivity, and falsely elevated serum digoxin concentrations with the fluorescence polarization immunomassay for digoxin.

Human hepatic stellate cells, isolated from wedge sections of normal human liver unsuitable for transplantation, were separated, after digestion with collagenase/pro- nase from other liver non-parenchymal cells by ultracentrifugation over gradients of stracate. Cells were cultured on plastic culture dishes in Iscove’s modified Dulbecco’s medium, supplemented as described elsewhere.3 Cells were isolated (1×10^6 cells in well dishes) and incubated with increasing concentrations of canrenone or with no drug (SFIF or control conditions), after a 24 hour incubation period in serum free insulin free (SFIF) medium. After 24 hours, medium was then been hypholised in a dry vacuum. Pellets were then resuspended in a total volume of 1 ml and aliquots of 200 μl were processed for aldosterone assay (Radim kit, Italy: KS171CT, RIA method). The results showed linearity (0.007 (0.003); 0.018 (0.004); 0.027 (0.003) nmol/l (mean (SD)); n = 3). As values obtained in SFIF samples were below the lower limit of the assay (0.009 (0.001)), it is conceivable that these cells do not produce aldosterone under basal conditions.4

To further validate this observation, we then spiked sera with increasing concentrations of canrenone (10, 50, 100 μM) and, subsequently, aldosterone concentrations were determined. Sera were collected from patients with different degrees of liver disease (from acute hepatitis (n = 1), to non-alcoholic steatohepatitis (n = 1), or chronic active hepatitis with (n = 3) or without (n = 6) cirrhosis). Aldosterone concentrations were as follows: 0.32 (0.18), 0.85 (0.26), and 1.07 (0.35) nmol/l (n = 11). Comparing these concentrations with the increasing concentrations of canrenone spiked into sera, a good linearity was found (from r = 0.874 to r = 0.988; p<0.0001).

To date, only positive interferences leading to falsely high digoxin readings, including those due to spironolactone and canrenone, have been reported.5 Negative interference is much more dangerous. Toxic concentrations may remain undetected. Less severe negative interferences or interferences from clinically less significant cross reagents have been reported. Assay manufacturers should assess potential cross reactivity in the presence of the primary ligand. This difficulty may apply to immunomasys and cross reactants other than digoxin and canrenone. Pathologists and clinicians should be aware of negative interference so that intoxication due to drug dosing guided by monitoring of its concentration in serum can be avoided. For positive interference of a low clinical weight substance, such as in our observation, false positive test results for hormonal and electrolyte disturbances during liver cirrhosis can be avoided.

These in vitro results can be considered effective in measuring aldosterone concentrations in plasma under in vivo conditions using a more cautious approach, as cross
reactivity could hardly affect biological determinations.

R G Romaneli, P Gentilini
Università degli Studi di Firenze, Dipartimento di Medicina Interna, Viale Morgagni, 85 50134 Florence, Italy
Correspondence to: Dr R G Romaneli; r.romaneli@uni.fi

References

Responses to endothelin-1 in patients with advanced cirrhosis before and after liver transplantation

In response to Helmy’s comments in his recent letter (Gut 2004;53:470–1), we wish to emphasize the following points, many of which were clearly stated in our original paper.

In agreement with the comments on “generalised vasodilatation” in cirrhosis, we made it clear that basal forearm blood flow was normal in our patient cohort despite the presence of a vasodilated circulation, as evidenced by a reduced systemic vascular resistance index. As pointed out in our paper, this observation is consistent with findings of previous studies and suggests that beds other than the forearm circulation, such as those of the splanchnic and pulmonary circulation, were dilated in our patients.

With regard to the issues raised about the use of one arm plethysmography, our own results and those of others have shown that under well controlled circumstances the results and those of others have shown that use of one arm plethysmography, our own

Correspondence to: Professor P W Angus; Peter.Angus@austin.org.au

References

Cluster’s last stand

Guthrie and colleagues (Gut 2003;52:1616–22) described the results of cluster analysis in a patient sample with severe irritable bowel syndrome (IBS). Their analysis investigated a broad range of factors in addition to symp-

toms; these included psychosocial measures (psychiatric involvement, health service encounters, quality of life) and physiological parameters (rectal thresholds). The authors have demonstrated that severe IBS can be classified according to nominated criteria and, in particular, according to the level of psychological distress, service encounters, and rectal sensitivity. They divide three groups which they labelled “disseminated high utilizers,” “distressed low utilizers”, and “tolerant low utilizers.” The authors defend their analysis on clinical grounds and point to treatment implications for each of these groups.

We feel that there are some fundamental points about the nature of cluster analysis that readers of this paper should not overlook. Cluster analysis was initially developed to create and/or evaluate classifications. Its application to gastrointestinal research has followed this approach. In recent years, clustering techniques have been applied to confirm that IBS and functional dyspepsia exist as separate clinical entities, and to evaluate specific syndrome subgroups, as described by the current Rome criteria. Following traditional clinical approaches, cluster solutions have generally been derived from symptom based parameters, including frequency, severity, and predominant complaint categories.

The term “cluster analysis” describes a range of procedures which use empirical methods to form groups of highly similar entities. While the notion that cluster analysis is solution seeking, or that these techniques is essentially solution imposing; that is, clustering methods will always place objects into groups. Furthermore, as there are no formal statistical procedures to evaluate the resulting solution, the reasonableness of any solution is determined only on the basis of personal judgement. This is a problem. Indeed, critics of the approach have argued that cluster analysis encourages “naive empiricism”—that is, inclusion of as many variables as possible in the hope that a meaningful structure will come out. However, proponents of cluster analysis have suggested that careful selection of variables on theoretical grounds can overcome this difficulty.

It is intuitively obvious that any single entity can be classified according to a broad range of dimensions, and Guthrie et al have certainly demonstrated this with respect to IBS. However, we rarely classify an entity according to all possible dimensions simultaneously; this would lead to a complex set of descriptors which may be unwieldy and contain many redundancies. Rather, we tend to select out a subset of meaningful dimensions that best suit our purposes in forming a classification.

There are certainly theoretical grounds for considering psychological involvement when evaluating patients and the association of IBS with psychological disturbance and health care seeking has been well described, and our understanding of these factors has contributed greatly to current therapeutic approaches. However, we challenge the proposed classification of IBS according to psychological involvement on two grounds. Firstly, we view this as a step towards naive empiricism; other researchers may be encouraged to replicate these analyses across a broader and even more diverse (yet irrelevant) range of dimensions. This is not likely to produce a parsimonious classification scheme that is useful in either clinical practice or research. Secondly, classification of IBS according to psychological and/or psychiatric involvement
Small bowel carcinoma and coeliac disease

We thank Howdle et al for their comments on our study, detailed recently in their letter (Gut 2003;53:470). In their British Society of Gastroenterology (BSG) National Survey,1 Howdle et al relied mainly on gastroenterologists and surgeons to report cases of small bowel carcinoma and whether they were associated with either coeliac or Crohn’s disease. This may have resulted in underestimation of associated coeliac disease. In our series, we had two cases in which the original pathologist had failed to recognise the histological features of coeliac disease. In our series, we had two cases in which the original pathologist had failed to recognise the histological features of coeliac disease. They may have resulted in underestimation of association with duodenal adenomas,2 the role of video capsule endoscopy of the entire small intestine needs to be explored.

P H R Green, S D Rampertab
Columbia University College of Physicians and Surgeons, New York, USA

References

Due to an administrative error, one article has been published on two occasions. The journal would like to retract the paper by Lindsay et al in the July issue (Gut 2003;52:981–7) as it is a replicated version of a paper by the same authors in the March issue (Gut 2003;52:363–9). The journal apologizes for this error.

British Society of Gastroenterology

Paul Brown Travel Fellowships

The Paul Brown Travel Fellowships are awarded by the Endoscopy Committee of the BSG. They are intended to assist trainee gastroenterologists and established consultants in visits to units outside the United Kingdom for special interest and training in endoscopy.

Specialist registrars who have not achieved their CCT may be expected to have the approval of their Postgraduate Dean and their Regional Training Director (RTD) before applying for a Travel Fellowship. Applicants are expected to provide confirmation that they have been accepted for training in the unit that they wish to visit.

Successful applicants will be expected to provide a brief written report to the Endoscopy Committee of the outcome of their visit.

Application forms are available from the British Society of Gastroenterology, 3 St Andrew’s Place, London NW1 4LB. Email: bsg@mailbox.ulcex.ac.uk

14th International Workshop of Digestive Endoscopy, Ultrasonography and Radiology

The 14th International Workshop of Digestive Endoscopy, Ultrasonography and Radiology will be held in Marseille on 27–28 May 2004. For further information, please contact: Nathalie Fontant, Atelier Phénix, 41 rue Docteur Morucci, 13006 Marseille (tel: (33) 04-91-37-50-83; fax: (33) 04-91-57-15-28; e-mail: nfontant@aphenix.com).

European Postgraduate Gastrointestinal School (EPGS) Courses 2004

The EPGS at the Academic Medical Center of the University of Amsterdam will be holding the following courses during the year: ‘Benign Hepato-Biliary Disorders’ will be held on 22 & 23 April 2004, ‘Endosonography live in Amsterdam’ will be held on 2, 3 & 4 June 2004, and ‘Update in Coloproctology’ will be held on 28 & 29 October 2004. For further information, please contact: J Goedkoop (tel: (31) 566 3926; fax: (33) 267 5594; e-mail: j.goedkoop@amc.uva.nl; website: www.epgs.nl).

8th Southeast European Symposium of Paediatric Surgery

The 8th Southeast European Symposium of Paediatric Surgery will focus upon ‘Infectious Problems in Paediatric Surgery.’ The event will be held between 24–25 September 2004, at the University of Graz, Austria. For further information, please contact: Professor M E Höllwarth, Department of Paediatric Surgery, Medical University of Graz, Austria, Auenbruggerplatz 34, 8036 Graz; tel: + 43 316 385 3762; fax: tel; + 43 316 385 3775; e-mail: kinderchirurgie@uni-graz.at.